Biohaven Taking Troriluzole Into Phase III OCD Study Despite Phase II/III Miss

Biohaven Pharmaceutical Holding Co. Ltd. reported Phase II/III results for the glutamate modulator troriluzole in obsessive-compulsive disorder (OCD) on 24 June that did not meet the clinical trial’s primary endpoint, but said the improvements versus placebo – particularly in patients with severe OCD – justify a Phase III clinical trial that will include a higher dose of the drug.

Biohaven emphasized its confidence in troriluzole, a prodrug of the generic amyotrophic lateral sclerosis (ALS) therapy riluzole, even though the candidate proved ineffective in another neuropsychiatric disorder earlier this year